Skip to content
Medical Health Aged Care

Viralgen welcomes back Andy Holt as CCO

Viralgen Vector Core 3 mins read

SAN SEBASTIAN, Spain, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Viralgen Vector Core (Viralgen) is pleased to welcome back their previous Executive Vice President of Commercial Development and Manufacturing, Andy Holt, into the newly created position of Chief Commercial Officer (CCO). In this role, Holt will lead Viralgen's commercial strategy towards achieving market-leading growth and customer centric solutions in gene therapy manufacturing.

Holt brings more than 15 years of experience in cell and gene therapy into his new role. His most recent position was CCO of Ncardia and Cellistic, affiliated companies leveraging deep experience in induced pluripotent stem cell (iPSC) technology to accelerate drug discovery and allogeneic cell therapy development. Prior to his first role with Viralgen, Holt held business development and management positions at MilliporeSigma (Merck KGaA) and Lonza.

"Viralgen has always worked hard to place the customer at the center of its business," said Jimmy Vanhove, CEO of Viralgen, "and having Andy return to the team to lead an evolving commercial organization, which includes Business Development, Marketing, and Project Management, is an exciting next step for us as we continue to fulfill our mission of producing revolutionary medicines on behalf of the customers and patients we serve."

"It's a privilege to return to Viralgen at an exciting time in our growth", says Holt. "We believe our team and capabilities lead the industry in meeting the manufacturing needs of gene therapy developers for uncompromising quality, agility, and cost effectiveness. Continuing to innovate, both in business and science, will enable us to remain a partner of choice, and this is an incredible opportunity that I am looking forward to supporting."

About Viralgen Vector Core
Viralgen is a Contract Development and Manufacturing Organization (CDMO) founded in 2017 and exists as an independently operated subsidiary of AskBio, which is wholly owned and independently operated as a subsidiary of Bayer AG. As a leading manufacturer of cGMP certified AAV, Viralgen offers the Pro10™ based suspension manufacturing platform, a technology licensed from AskBio and developed by Chief Technical Officer Josh Grieger, PhD, and co-founder R. Jude Samulski, PhD, at University of North Carolina. It has been demonstrated  that Pro10™ increases scalability, performance, and yield of AAV therapies1 at Viralgen and previous partners of AskBio. Located in Spain, in the Gipuzkoa Science and Technology Park, Viralgen produces AAV gene therapy treatments for pharmaceutical and biotech companies with the aim of accelerating the delivery of new treatments that can improve patients' lives

The company's clinical facilities have four cGMP manufacturing suites, with 250-liter and 500-liter bioreactors. In 2020, Viralgen expanded within the Scientific Park by constructing a new building for large-scale commercial manufacturing. The new state-of-the-art space includes three additional cGMP suites with a manufacturing capacity of >2,000 liters each, as well as a suite dedicated to fully automated fill and finish operations. The new facility has received the cGMP certification by the Spanish Agency for Medicines and Medical Devices (AEMPS) as part of the EMA network. For more information, visit

1 Mol Ther. 2016 Feb;24(2):287-297. doi: 10.1038/mt.2015.187. Epub 2015 Oct 6.

For more information and interviews, please contact:
Priscilla Assumpção

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit


More from this category

  • Medical Health Aged Care
  • 01/03/2024
  • 09:00
Dementia Australia

Dementia Australia supports Limestone Coast

Are you concerned about your memory or worried that someone you know may have dementia? Dementia Australia is offering support in Limestone Coast between 15 March and 9 April. It is estimated there are more than 34,700 people living with dementia in South Australia. Without a medical breakthrough this number is expected to increase to more than 55,200 people living with dementia by 2054. The Dementia Australia sessions are an opportunity for people living with dementia, their carers, family, and friends to attend free education to better understand dementia and to discuss the support and services Dementia Australia can provide.…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 01/03/2024
  • 06:01
Leukaemia Foundation

Leukaemia Foundation calls for greater awareness of myeloma as incidence rates set to more than double by 2035?

With myeloma incidence rates set to more than double by 2035, the Leukaemia Foundation is urgently calling for greater awareness and equitable access to treatment across the country, so myeloma patients have the best chance of survival, no matter where they live. As Myeloma Awareness Month launches today, Leukaemia Foundation CEO Chris Tanti said while survival rates for some blood cancers are improving, those diagnosed with myeloma still face a 50/50 chance of survival. “As many as 4 in 5 Australians are not confident in recognising the main symptoms of a blood cancer, like myeloma, leaving them at risk of…

  • Medical Health Aged Care
  • 01/03/2024
  • 06:00
Issued by Cube on behalf of Arthritis Australia

Arthritis Australia welcomes cheaper arthritis medicines

MEDIA RELEASE: 1st March 2024 More medicines now eligible for 60 day dispensing from March 1 2024 [Sydney, Australia] Arthritis Australia has welcomed access to cheaper medicines commonly used to treat arthritis, with the rollout of a new tranche of medicines eligible for 60 day dispensing from March 1 2024. Doctors will be able to write a 12-month script for medicines commonly used for arthritis conditions, including prednisolone, methotrexate DBL, Leflunomideand Ciclosporin, allowing a two-month supply to be dispensed when patients visit their pharmacy. Arthritis Australia CEO Jonathan Smithers said “Many people living with arthritis who are struggling with the…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.